Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported
Outcomes-16-Week Results from a Placebo-controlled Phase 2
Study in Patients with Active Psoriatic Arthritis

a 2022

Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

TAYLOR, Peter, Frank BEHRENS, Philip J. MEASE, Dieter WETZEL, Paul PELOSO et. al.

Basic information

Original name

Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

Authors

TAYLOR, Peter, Frank BEHRENS, Philip J. MEASE, Dieter WETZEL, Paul PELOSO, Nicolai BRUN, Brian WIENS, Jan BRANDTJUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Kurt DE VLAM

Edition

2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 13.300

RIV identification code

RIV/00216224:14160/22:00128083

Organization unit

Faculty of Pharmacy

ISSN

UT WoS

000877386500199

Keywords in English

Izokibep; IL-17A inhibitor; patient outcomes; psoriatic arthriris; clinical trial

Abstract

V originále

Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a key driver of the PsA disease process, which greatly impacts patients’ physical function, vitality, social participation, mood, and quality of life. Here, we report 16-week results of izokibep on patient-reported outcomes (PROs) in adult patients with active PsA.

Citovat

TAYLOR, Peter, Frank BEHRENS, Philip J. MEASE, Dieter WETZEL, Paul PELOSO, Nicolai BRUN, Brian WIENS, Jan BRANDTJUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Kurt DE VLAM. Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis. 2022. ISSN 2326-5191.

@proceedings{2247558,
   author = {Taylor, Peter and Behrens, Frank and Mease, Philip J. and Wetzel, Dieter and Peloso, Paul and Brun, Nicolai and Wiens, Brian and Brandtjuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and Martin, Nadia AbdelandKader and de Vlam, Kurt},
   keywords = {Izokibep; IL-17A inhibitor; patient outcomes; psoriatic arthriris; clinical trial},
   language = {eng},
   title = {Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis},
   url = {https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/},
   year = {2022}
}

TY  - CONF
ID  - 2247558
AU  - Taylor, Peter - Behrens, Frank - Mease, Philip J. - Wetzel, Dieter - Peloso, Paul - Brun, Nicolai - Wiens, Brian - Brandtjuergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Martin, Nadia Abdel-Kader - de Vlam, Kurt
PY  - 2022
TI  - Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
KW  - Izokibep
KW  - IL-17A inhibitor
KW  - patient outcomes
KW  - psoriatic arthriris
KW  - clinical trial
UR  - https://acrabstracts.org/abstract/izokibep-a-novel-il-17a-inhibitor-improves-patient-reported-outcomes-16-week-results-from-a-placebo-controlled-phase-2-study-in-patients-with-active-psoriatic-arthritis/
N2  - Izokibep is a unique IL-17A inhibitor with high potency and small molecular size designed to overcome the limitations of monoclonal antibodies. IL-17 is a key driver of the PsA disease process, which greatly impacts patients’ physical function, vitality, social participation, mood, and quality of life. Here, we report 16-week results of izokibep on patient-reported outcomes (PROs) in adult patients with active PsA.
ER  -

TAYLOR, Peter, Frank BEHRENS, Philip J. MEASE, Dieter WETZEL, Paul PELOSO, Nicolai BRUN, Brian WIENS, Jan BRANDTJUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Nadia Abdel-Kader MARTIN and Kurt DE VLAM. \textit{Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes-16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis}. 2022. ISSN~2326-5191.

Detailed Information on Publication Record